Eggermont, A. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., van den Eertwegh, A. J., Grob, J., Gutzmer, R., Jamal, R., Lorigan, P. C., Lupinacci, R., Krepler, C., Ibrahim, N., Kicinski, M., Marreaud, S., van Akkooi, A. C., Suciu, S., & Robert, C. (2019). prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. European journal of cancer, 116, 148–157. http://access.bl.uk/ark:/81055/vdc_100086505541.0x000022